About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 426 record(s)
Req # A-2021-000424
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-102006-568.Organization: Health Canada
August 2023
Req # A-2021-000801
Adverse Drug Reaction (ADR) for ALENDRONATE SODIUM. Report number: E2B_03328390.Organization: Health Canada
August 2023
Req # A-2021-002129
Adverse Drug Reactions (ADRs) for METRONIDAZOLE, IRBESARTAN. Report numbers: E2B_04927112, 000972078, 000972569, 000972665, 000972188.Organization: Health Canada
August 2023
Req # A-2022-000481
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105061-143.Organization: Health Canada
August 2023
Req # A-2022-001067
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-111407-100.Organization: Health Canada
August 2023
Req # A-2022-001252
Adverse Drug Reactions (ADRs) for VEDOLIZUMAB. Report numbers: E2B_05801639, E2B_05868878, E2B_05823260. ADRs for C1 ESTERASE INHIBITOR. Report numbers: E2B_05801639, E2B_05868878, E2B_05823260.Organization: Health Canada
August 2023
Req # A-2022-001455
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-112998-845.Organization: Health Canada
August 2023
Req # A-2022-001456
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-113333-209.Organization: Health Canada
August 2023
Req # A-2022-001512
Adverse Drug Reactions (ADRs). Report numbers: 001025815, E2B_06026927.Organization: Health Canada
August 2023
Req # A-2023-000042
Adverse Drug Reactions (ADRs). Report numbers: 000913347, 000915274, 000918468, E2B_03533065, 000975599, E2B_04124641, E2B_04491922, 000969801, 000946974, 000933140.Organization: Health Canada
August 2023